Live Breaking News & Updates on Hematologic Malignancy Expansion Cohorts

Published: May 11, 2021
- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 -
- Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 -
- Dose Escalation Ongoing in Phase 1 Trial of Oral MCL1 Inhibitor PRT1419, with Dose Expansion Cohorts on Track to be Added in 2H21 -
WILMINGTON, Del., May 11, 2021 (GLOBE NEWSWIRE) Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent clinical and development pipeline progress. ....

United States , Kris Vaddi , Deborah Elson , Melissa Forst , Exchange Commission , Development Rd Expenses , American Association For Cancer Research , Company Phase , Prelude Therapeutics Inc , Drug Administration , Now Under Way , Multiple Solid Tumor , Hematologic Malignancy Expansion Cohorts , Clinical Data Readouts , Lead Oral , Escalation Ongoing , Dose Expansion Cohorts , Chief Executive , Data Featured , American Association , Cancer Research , Annual Meeting , Prelude Therapeutics , Expansion Cohorts Remain , Planned Dose Expansion , Combination Cohorts Expected ,